05:05 AM EST, 11/10/2025 (MT Newswires) -- Metsera ( MTSR ) said late Friday it signed an amended merger agreement with Pfizer ( PFE ) under which Pfizer ( PFE ) will acquire Metsera ( MTSR ) for up to $86.25 per share.

The new consideration consists of $65.60 per share in cash and a contingent value right entitling holders to additional payments of up to $20.65 per share in cash.

Metsera ( MTSR ) said it's board has determined that the revised terms represent the "best transaction" for its shareholders and that the deal proposed by Novo Nordisk ( NVO ) presents "unacceptably high legal and regulatory risks."

The companies expect the deal to close following the Metsera's ( MTSR ) stockholder meeting Thursday

Novo Nordisk ( NVO ) said over the weekend it doesn't plan to make an increased offer for Metsera ( MTSR ). On Thursday, the company submitted a revised unsolicited proposal at a price of $65.60 per share in cash and contingent value rights for up to $20.65 per share in cash.

Metsera ( MTSR ) shares were down 15% in recent premarket activity Monday, while Pfizer ( PFE ) rose 0.7%. Novo Nordisk ( NVO ) was up 1.8%.